Safety & Side Effects

What we know, what we do not, and the cancer question

Short-term, thymosin beta-4 looks reasonably well tolerated in trials, with mostly minor reported effects. The serious, unresolved issue is its relationship with cancer: the same protein is upregulated in several aggressive tumors, yet suppresses others. The evidence is correlational, not settled.

This unit separates the reassuring short-term data from the genuine long-term gaps, walks the nuanced cancer picture in both directions, and lays out who should be most cautious.